Search research articles
Contact Us
Filters
Showing results (151-160 of 280) with videos related to
Page
of 28
Sort By:
Journal of Clinical Pharmacology
|
April 21, 2016
Integrating Dynamic Positron Emission Tomography and Conventional Pharmacokinetic Studies to Delineate Plasma and Tumor Pharmacokinetics of FAU, a Prodrug Bioactivated by Thymidylate Synthase
Jing Li, Seongho Kim, Anthony F Shields, et al.
Investigational New Drugs
|
January 1, 1996
Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks
B J Foster, P M LoRusso, E Poplin, et al.
Plos One
|
March 17, 2015
Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer
Julie L Boerner, Nicole Nechiporchik, Kelly L Mueller, et al.
The Lancet. Oncology
|
May 6, 2014
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Ian E Krop, Sung-Bae Kim, Antonio González-Martín, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 8, 2005
Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design
Shirish M Gadgeel, Antoinette Wozniak, Ramesh R Boinpally, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2005
Differentiation and definition of vascular-targeted therapies
Dietmar W Siemann, Michael C Bibby, Graham G Dark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 2, 2025
FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and Biomarkers
Olanrewaju O Okusanya, Gabriela I Patilea-Vrana, Anthony Sireci, et al.
The Oncologist
|
March 20, 2021
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
Joseph W Kim, Dana B Cardin, Ulka N Vaishampayan, et al.
Investigational New Drugs
|
September 16, 2010
A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors
Aung Naing, Razelle Kurzrock, Laurel M Adams, et al.
Targeted Oncology
|
June 15, 2014
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study
Irene Brana, Antonio Calles, Patricia M LoRusso, et al.
Page
of 28
Search research articles
Search
Showing results (151-160 of 280) with videos related to
Sort By:
Page
of 28
Journal of Clinical Pharmacology
|
April 21, 2016
Integrating Dynamic Positron Emission Tomography and Conventional Pharmacokinetic Studies to Delineate Plasma and Tumor Pharmacokinetics of FAU, a Prodrug Bioactivated by Thymidylate Synthase
Jing Li, Seongho Kim, Anthony F Shields, et al.
Investigational New Drugs
|
January 1, 1996
Phase I trial of Adozelesin using the treatment schedule of daily x5 every 3 weeks
B J Foster, P M LoRusso, E Poplin, et al.
Plos One
|
March 17, 2015
Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer
Julie L Boerner, Nicole Nechiporchik, Kelly L Mueller, et al.
The Lancet. Oncology
|
May 6, 2014
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Ian E Krop, Sung-Bae Kim, Antonio González-Martín, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 8, 2005
Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design
Shirish M Gadgeel, Antoinette Wozniak, Ramesh R Boinpally, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 11, 2005
Differentiation and definition of vascular-targeted therapies
Dietmar W Siemann, Michael C Bibby, Graham G Dark, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 2, 2025
FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and Biomarkers
Olanrewaju O Okusanya, Gabriela I Patilea-Vrana, Anthony Sireci, et al.
The Oncologist
|
March 20, 2021
Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
Joseph W Kim, Dana B Cardin, Ulka N Vaishampayan, et al.
Investigational New Drugs
|
September 16, 2010
A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors
Aung Naing, Razelle Kurzrock, Laurel M Adams, et al.
Targeted Oncology
|
June 15, 2014
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study
Irene Brana, Antonio Calles, Patricia M LoRusso, et al.
Page
of 28